Get the Stockscreener App
4.35
15.38%
0.58
After Hours:
4.42
0.07
+1.61%
Sellas Life Sciences Group Inc stock is traded at $4.35, with a volume of 30.22M.
It is up +15.38% in the last 24 hours and up +212.95% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$3.77
Open:
$4.45
24h Volume:
30.22M
Relative Volume:
5.10
Market Cap:
$619.62M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-3.1985
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
+51.57%
1M Performance:
+212.95%
6M Performance:
+105.19%
1Y Performance:
+306.54%
1-Day Range:
$3.96
$4.66
1-Week Range:
$2.60
$4.66
52-Week Range:
$0.8505
$4.66
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
4.35 | 537.01M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
Best Penny Stocks To Follow TodayJanuary 4th - MarketBeat
SELLAS Life Sciences Stock Surges as Phase 3 Trial Nears Data Trigger - StocksToTrade
Promising Penny Stocks To Add to Your WatchlistJanuary 1st - MarketBeat
Penny Stocks To Follow TodayJanuary 3rd - MarketBeat
Why Is SLS Stock Drawing Significant Investor Attention Today? - Asianet Newsable
Ironwood Pharmaceuticals, Baidu, Vertiv Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
SELLAS Life Sciences Group Stock (SLS) Opinions on Phase 3 Trial Progress - Quiver Quantitative
SELLAS Life Sciences Group stock soars as it nears final analysis in cancer study - MSN
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus - ts2.tech
Sellas Life Sciences Showcases Promising Phase 2 Data at Annual Meeting - StocksToTrade
Sellas Life Sciences Showcases Breakthroughs in AML Treatment - timothysykes.com
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
Largest borrow rate increases among liquid names - TipRanks
SELLAS Life Sciences Stock Surge: Buy or Wait? - StocksToTrade
SELLAS’s Therapy Triumph: Market Buzz - timothysykes.com
Discover the Top 5 Small-Cap Biotech Stocks in 2025 - Investing News Network
CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday - Benzinga
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia - marketscreener.com
SELLAS Reports Continued Progress In Phase 3 REGAL Trial Of GPS In Acute Myeloid Leukemia - Nasdaq
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next - ts2.tech
Sellas Life Sciences Stock Surges After Positive Clinical Trials - StocksToTrade
SELLAS Life Sciences Stock Is Surging Higher: What's Going On? - Benzinga
Sellas Life Sciences stock soars after trial update shows slower event rate - Investing.com Nigeria
Sellas Life Sciences stock soars after trial update shows slower event rate By Investing.com - Investing.com Australia
SELLAS Life Sciences (SLS) Stock: Shows Bullish Momentum Ahead of Pivotal AML Data Readout - parameter.io
SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study - Stocktwits
SLS Stocks Surge As New Phase 2 Results Show Promising Outcomes - timothysykes.com
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Sellas Life Sciences Says 72 Deaths Have Occurred in Phase 3 Acute Myeloid Leukemia Trial - marketscreener.com
Sellas Life Sciences says REGAL trial CRO informs company 72 events occurred - TipRanks
SELLAS reports 72 events in Phase 3 REGAL trial, awaits final analysis - Investing.com
Leukemia study awaits 80th death to trigger final analysis - Stock Titan
Why Vinci Partners Investments Ltd. stock remains undervaluedEarnings Growth Patterns & Affordable Portfolio Growth - bollywoodhelpline.com
Will TKNO stock benefit from upcoming earnings reportsTrend Following Strategies & Free Superior Profit Margins - bollywoodhelpline.com
Is It Too Late to Sell STEL Holdings LimitedGrowth Stock Opportunities & Small Capital Wealth Plans - bollywoodhelpline.com
How Is The Market Feeling About SELLAS Life Sciences Group Inc? - Benzinga
SELLAS Life Sciences (SLS) Is Up 34.6% After Leukemia Data Update Has The Bull Case Changed? - simplywall.st
Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations - Yahoo Finance
SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? - Stocktwits
SELLAS Surge: Analyzing the Latest Performance - StocksToTrade
SELLAS Life Sciences Soars: A Game-Changer? - timothysykes.com
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
SELLAS Life Sciences Group, Inc. Stock (SLS) Opinions on Clinical Trial Results - Quiver Quantitative
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025) - ts2.tech
Sellas Life Sciences: Ready for a Breakthrough? - StocksToTrade
Sellas Life Sciences Nears Critical Inflection Point - AD HOC NEWS
Aug Drivers: Is SELLAS Life Sciences Group Inc RXK3 stock trading at attractive multiplesWeekly Trade Analysis & Consistent Return Strategy Ideas - moha.gov.vn
Jumping in during volatile news — sit outSell Signals and Alerts & Invest Smarter With Signals - Bollywood Helpline
What Wall Street predicts for SELLAS Life Sciences Group Inc. stock priceTreasury Yields & Daily Chart Pattern Signals - Улправда
Is SELLAS Life Sciences Group Inc. stock affected by interest rate hikes2025 Volume Leaders & Safe Entry Zone Tips - Улправда
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):